MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Hold” from Brokerages

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have earned an average rating of “Hold” from the seventeen research firms that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $24.2143.

Several equities research analysts recently issued reports on MLTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of MoonLake Immunotherapeutics in a report on Monday. BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. Needham & Company LLC increased their price objective on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Finally, Leerink Partners raised their price objective on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st.

Trending Headlines about MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Neutral Sentiment: HC Wainwright reaffirmed a bullish stance on MoonLake Immunotherapeutics, keeping a Buy rating and $45 price target in place. HC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
• Positive Sentiment: Analysts improved near-term earnings estimates for Q2 2026, Q3 2026, Q4 2026, and Q1 2027, suggesting slightly better expected operating performance in the next several quarters.
• Positive Sentiment: FY2026 and FY2027 loss forecasts were also reduced, which may be interpreted as a modest improvement in the company’s longer-term earnings path.
• Negative Sentiment: Q3 2027 earnings estimates were cut, and the stock may be under pressure because investors are focusing on the mixed nature of the revisions rather than the Buy rating.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 68,289 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the sale, the chief executive officer directly owned 2,774,893 shares of the company’s stock, valued at $55,553,357.86. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $19.43, for a total value of $971,500.00. Following the completion of the transaction, the insider owned 2,824,551 shares in the company, valued at $54,881,025.93. The trade was a 1.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 250,000 shares of company stock valued at $4,919,138 in the last ninety days. 10.40% of the stock is currently owned by insiders.

Institutional Trading of MoonLake Immunotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC bought a new position in MoonLake Immunotherapeutics in the 4th quarter worth approximately $26,000. FNY Investment Advisers LLC bought a new stake in shares of MoonLake Immunotherapeutics during the third quarter valued at approximately $28,000. Bank of America Corp DE raised its position in shares of MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after buying an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after buying an additional 3,166 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after buying an additional 1,069 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Price Performance

NASDAQ MLTX opened at $18.94 on Thursday. The business’s fifty day moving average is $18.92 and its 200 day moving average is $17.59. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.60 and a current ratio of 8.60. The company has a market capitalization of $1.39 billion, a PE ratio of -4.89 and a beta of 1.04.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.07). Sell-side analysts predict that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.